Cargando…
Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
Axitinib, small molecule tyrosine kinase inhibitor, demonstrates anti-cancer activity for various solid tumors. We investigated anti-cancer effect of axitinib in epithelial ovarian cancer (EOC). We treated EOC cells (A2780, HeyA8, RMG1, and HeyA8-MDR) with axitinib to evaluate its effects on cell vi...
Autores principales: | Paik, E Sun, Kim, Tae-Hyun, Cho, Young Jae, Ryu, Jiyoon, Choi, Jung-Joo, Lee, Yoo-Young, Kim, Tae-Joong, Choi, Chel-Hun, Kim, Woo Young, Sa, Jason K., Lee, Jin-Ku, Kim, Byoung-Gie, Bae, Duk-Soo, Han, Hee Dong, Ahn, Hyung Jun, Lee, Jeong-Won |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078214/ https://www.ncbi.nlm.nih.gov/pubmed/32184452 http://dx.doi.org/10.1038/s41598-020-61871-w |
Ejemplares similares
-
Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2016) -
Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2016) -
Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis
por: Paik, E Sun, et al.
Publicado: (2018) -
Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification
por: Paik, E Sun, et al.
Publicado: (2015) -
Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
por: Jeong, Soo Young, et al.
Publicado: (2019)